The global PARP inhibitor biomarkers market size is likely to be valued at US$1.1 billion in 2026, and is expected to reach US$2.0 billion by 2033, growing at a CAGR of 8.8% during the forecast period from 2026 to 2033, driven by the expanding approvals of PARP inhibitor therapies, with each new approved indication requiring a corresponding companion or complementary biomarker test. This prescription-driven demand model supports consistent market growth and remains largely independent of broader laboratory testing trends.

Driver– Shifting from Single-Gene BRCA Testing to Pan-HRR Gene Panel Biomarker Analysis

The clinical evidence supporting PARP inhibitors continues to expand. Their use is no longer limited to germline BRCA1/2 mutations. Researchers are evaluating their effectiveness across a wider range of homologous recombination repair (HRR) gene alterations. These include somatic BRCA1/2, PALB2, RAD51C, RAD51D, CDK12, ATM, and CHEK2 mutations. Genomic instability-based HRD scores are also being used to predict PARP inhibitor response. These scores can identify patients who may benefit even without a specific gene mutation.

This shift from a single-gene BRCA test to multi-gene HRR panels inherently increases the revenue per test event due to the greater analytical complexity, higher NGS sequencing content, and bioinformatics interpretation requirements of comprehensive HRR testing compared to single-gene BRCA analysis. According to the National Cancer Institute (NCI), approximately 5-7% of epithelial ovarian cancers harbor germline BRCA mutations, and an additional 22% carry somatic HRR alterations, indicating that BRCA-alone testing misses a clinically significant portion of PARP inhibitor-eligible patients, creating a strong clinical and commercial argument for comprehensive HRR biomarker panel adoption.

Restraint – Inadequate Tumor Tissue Availability and Growing Need for Liquid Biopsy Alternatives

PARP inhibitor biomarker testing using tumor tissue biopsy faces several challenges. Adequate tumor samples are not always available. Repeated biopsies in patients with metastatic disease can increase clinical risk. Some metastatic tumors are difficult to access. In other cases, biopsy samples contain too few tumor cells for comprehensive molecular testing. This can prevent NGS-based HRR and HRD analysis.

Guardant Health developed the Guardant360 CDx liquid biopsy platform to address this challenge. The test received FDA approval as a companion diagnostic for olaparib in metastatic castration-resistant prostate cancer (mCRPC). It analyzes circulating tumor DNA instead of tissue samples. However, clinical validation for liquid biopsy-based HRD and HRR testing is still less established than tissue-based testing. As a result, liquid biopsy is mainly used when tissue samples are insufficient rather than as the primary testing method.

Opportunity– Liquid Biopsy-Based PARP Inhibitor Biomarker Testing for Treatment Monitoring and Resistance Detection

Liquid biopsy-based circulating tumor DNA (ctDNA) analysis offers benefits beyond initial patient selection. It enables real-time monitoring of PARP inhibitor treatment response. It can also help detect acquired resistance at an early stage. Key resistance mechanisms include BRCA reversion mutations, RAD51 paralog alterations, and PARP1 mutations. These changes can restore HRR function and reduce the effectiveness of PARP inhibitors.

A validated liquid biopsy platform for detecting these resistance mutations would create a significant clinical opportunity. It could help physicians switch therapies before disease progression becomes clinically evident. This approach would extend PARP inhibitor biomarker testing beyond a one-time pre-treatment assessment. Instead, testing could continue throughout the treatment period. This would support ongoing treatment management while generating recurring testing revenue.

Product Type Insights

Kits are expected to dominate the product segment, accounting for approximately 61% of total revenue in 2026. Growth is driven by the multi-step nature of NGS-based homologous recombination repair (HRR) testing, which requires DNA extraction kits, library preparation kits, sequencing reagent kits, and bioinformatics software within a single workflow. The use of multiple kits per test generates higher revenue than assay-based services. Illumina's TruSight Oncology 500 (TSO 500) is widely used for oncology biomarker profiling, including homologous recombination deficiency (HRD) assessment to support PARP inhibitor patient selection.

Assays are projected to be the fastest-growing product segment, driven by the increasing adoption of FDA-approved companion diagnostic services and the growing preference among oncology centers to outsource HRR and HRD biomarker testing to certified reference laboratories. This approach eliminates the need for hospitals to establish in-house NGS testing capabilities. Foundation Medicine offers FoundationOne CDx, while Myriad Genetics provides BRACAnalysis CDx and myChoice CDx, with the latter performed through Myriad's centralized certified laboratory, enabling healthcare providers to outsource HRD and BRCA testing efficiently.

Service Insights

BRCA1 & BRCA2 testing is expected to dominate the service segment, accounting for approximately 48% of total revenue in 2026, driven by its established role as the primary companion diagnostic for most approved PARP inhibitor therapies. Myriad Genetics' BRACAnalysis CDx serves as the FDA-approved companion diagnostic for olaparib in breast and pancreatic cancers and talazoparib in breast cancer for germline BRCA mutation testing, making it one of the highest-revenue companion diagnostic services in the PARP inhibitor market.

HRD testing is projected to be the fastest-growing service segment, driven by the FDA approval of myChoice CDx as a companion diagnostic for niraparib and olaparib in ovarian cancer. Expanding clinical evidence supports the use of HRD score-based patient selection beyond patients with BRCA mutations, broadening the eligible treatment population. In addition, HRD testing is gaining traction in breast cancer, with ongoing clinical studies evaluating its role in neoadjuvant and early-stage treatment settings and investigating HRD status as a predictor of response to PARP inhibitor therapies.

Technology Insights

Next-generation sequencing (NGS) is expected to dominate the technology segment, accounting for nearly 52% of total revenue in 2026. Growth is driven by its ability to detect both germline and somatic BRCA1/2 mutations in a single test while simultaneously analyzing comprehensive homologous recombination repair (HRR) gene panels and genomic instability signatures for homologous recombination deficiency (HRD) scoring. These capabilities make NGS the preferred technology for PARP inhibitor biomarker testing across clinical oncology centers.

Polymerase chain reaction (PCR) is projected to be the fastest-growing technology segment, driven by the increasing adoption of PCR-based BRCA hotspot mutation testing panels. These assays offer rapid turnaround times and cost-effective BRCA screening, making them particularly well suited for resource-constrained healthcare settings and routine clinical testing.

Application Insights

Breast cancer is expected to dominate the application segment, accounting for over 52% of total revenue in 2026. Growth is driven by the strong association between BRCA1/BRCA2 mutations and hereditary breast cancer, along with clinical guidelines recommending BRCA testing for patients with early-onset breast cancer, triple-negative breast cancer, and a significant family history of the disease. These recommendations generate the highest biomarker testing volumes across all cancer indications. Approximately 5–10% of breast cancer cases are hereditary, with BRCA mutations representing one of the most significant inherited risk factors.

Prostate cancer is projected to be the fastest-growing application segment, driven by the expanding use of precision oncology and the increasing adoption of BRCA testing to identify patients eligible for PARP inhibitor therapies. Clinical guidelines now recommend both germline and somatic BRCA testing for patients with metastatic and advanced prostate cancer. Rising awareness of hereditary cancer syndromes in men is further supporting the growth of biomarker testing in this segment.

North America PARP Inhibitor Biomarkers Market Trends

North America is projected to dominate the market, accounting for approximately 46% of total global revenue in 2026. The region benefits from the U.S. FDA's established companion diagnostic approval framework. It also records the world's highest PARP inhibitor prescription volumes. The presence of leading commercial biomarker testing companies further supports market growth.

U.S. PARP Inhibitor Biomarkers Market Trends

The U.S. is expected to account for approximately 91% of North American revenue in 2026, driven by its position as the largest commercial market for approved PARP inhibitor companion diagnostics. The country's high incidence of PARP inhibitor-eligible cancers continues to support strong demand for biomarker testing. According to the American Cancer Society, approximately 321,910 new breast cancer cases and 60,730 new ovarian cancer cases are diagnosed annually in the U.S., creating a substantial patient population for BRCA1/2 and HRD biomarker testing.

Canada PARP Inhibitor Biomarkers Market Trends

Canada is projected to account for nearly 9% of North American revenue in 2026, driven by the growing adoption of BRCA and homologous recombination repair (HRR) biomarker testing across provincial cancer programs. Market growth is further supported by the integration of these tests with provincial reimbursement and PARP inhibitor formulary listings, as well as broader hereditary BRCA testing recommendations under the Canadian College of Medical Geneticists (CCMG) guidelines.

Europe PARP Inhibitor Biomarkers Market Trends

Europe is expected to account for approximately 30% of global revenue in 2026 and is projected to grow at a CAGR of 8.5% from 2026 to 2033. Growth is driven by the region's well-established oncology pharmacogenomics infrastructure, supported by the European Medicines Agency (EMA) companion diagnostic approval framework and the EU In Vitro Diagnostic Regulation (IVDR). In addition, ongoing national genomic medicine initiatives are accelerating the adoption of biomarker testing across clinical oncology settings.

U.K. PARP Inhibitor Biomarkers Market Trends

The U.K. is expected to account for approximately 24% of European revenue in 2026, driven by the expansion of NHS England's Genomic Medicine Service (GMS). The network of seven Genomic Laboratory Hubs (GLHs) has established standardized pathways for BRCA and homologous recombination repair (HRR) testing, improving patient access to biomarker diagnostics and supporting the broader adoption of PARP inhibitor therapies across the country.

Germany PARP Inhibitor Biomarkers Market Trends

Germany is expected to account for approximately 21% of European revenue in 2026, driven by its well-established hospital molecular pathology network and widespread adoption of advanced genomic diagnostics. Comprehensive cancer centers increasingly utilize FoundationOne CDx for homologous recombination repair (HRR) profiling, while the presence of QIAGEN with major operations in Germany further reinforces the country's position as a leading hub for molecular diagnostics innovation and precision oncology.

Asia Pacific PARP Inhibitor Biomarkers Market Trends

Asia Pacific is projected to be the fastest-growing regional market, registering a CAGR of 11.2% from 2026 to 2033. Growth is driven by expanding approvals of PARP inhibitor therapies by regulatory agencies such as the PMDA (Japan), NMPA (China), and CDSCO (India), alongside increasing investments in oncology genomics infrastructure. In addition, the growing body of clinical evidence on BRCA mutation prevalence among Asian populations is supporting wider adoption of biomarker testing and precision oncology.

China PARP Inhibitor Biomarkers Market Trends

China is expected to account for approximately 31% of Asia Pacific revenue in 2026, making it the region's largest market for PARP inhibitor biomarkers. Growth is driven by the NMPA's approval of olaparib and niraparib for ovarian cancer, accompanied by companion diagnostic requirements that are accelerating biomarker testing adoption. In addition, Amoy Diagnostics has developed an NMPA-approved BRCA1/2 mutation detection kit for olaparib, highlighting the rapid expansion of China's domestic companion diagnostics industry.

India PARP Inhibitor Biomarkers Market Trends

India is expected to account for nearly 22% of Asia Pacific revenue in 2026, driven by the increasing adoption of hereditary BRCA testing across private oncology hospitals. Market growth is further supported by a growing body of clinical studies documenting BRCA mutation prevalence among Indian patients with breast and ovarian cancers. In addition, the expanding availability of affordable BRCA testing through domestic molecular diagnostics companies and regional next-generation sequencing (NGS) service providers is improving access to precision oncology diagnostics.

The global PARP inhibitor biomarkers market has a two-tier competitive landscape. The first tier comprises integrated molecular oncology diagnostics companies with FDA-approved companion diagnostics, providing significant regulatory and commercial advantages. The second tier consists of next-generation sequencing (NGS) platform providers, hereditary genetic testing specialists, and regional molecular diagnostics companies competing in the BRCA, homologous recombination deficiency (HRD), and homologous recombination repair (HRR) testing segments.

Foundation Medicine and Myriad Genetics are among the leading players in the market, driven by their FDA-approved companion diagnostic portfolios. FoundationOne CDx offers comprehensive genomic profiling to identify patients eligible for PARP inhibitor therapies across multiple tumor types, while Myriad Genetics' BRACAnalysis CDx and myChoice CDx are widely adopted for hereditary BRCA mutation and HRD testing, reinforcing the company's strong position in precision oncology diagnostics.

Key Industry Developments:

• In 2023, Foundation Medicine (Roche) received FDA supplemental approval for FoundationOne CDx as a companion diagnostic for olaparib (Lynparza) in germline BRCA-mutated HER2-negative early breast cancer following the OlympiA trial data, expanding the companion diagnostic’s approved indication from metastatic to early-stage breast cancer and substantially increasing the addressable BRCA testing population for PARP inhibitor patient selection.
• In 2024, Guardant Health advanced its liquid biopsy PARP inhibitor biomarker platform with expanded HRR gene panel coverage on its Guardant360 CDx assay, targeting regulatory submission for additional PARP inhibitor companion diagnostic approvals in ovarian and breast cancer indications to expand its liquid biopsy companion diagnostic footprint beyond the existing mCRPC olaparib approval.